Indole-3-propionic acid connects gastrointestinal impairment to diabetic retinopathy: a potential biomarker and innovative treatment strategy - Takeaway - MDSpire

Indole-3-propionic acid connects gastrointestinal impairment to diabetic retinopathy: a potential biomarker and innovative treatment strategy

Share

  • 1

    Diabetic retinopathy (DR) is linked to gut-retinal axis disruption and impaired tryptophan metabolism.

  • 2

    Indole-3-propionic acid (IPA) levels are significantly lower in individuals with DR compared to those without retinopathy.

  • 3

    Supplementation with IPA in a T2D mouse model reduces hyperglycemia and intestinal inflammation, preventing DR development.

  • 4

    Activation of the ACE2-dependent pathway enhances tryptophan absorption, improving gut barrier function and incretin secretion.

  • 5

    The study suggests IPA as a potential biomarker for DR and highlights nutraceuticals as innovative therapeutic strategies.

Original Source(s)

Indole-3-propionic acid connects gastrointestinal impairment to diabetic retinopathy: a potential biomarker and innovative treatment strategy

  • by Ram Prasad, Yvonne Adu-Rutledge, Borhane Ziani, Jason L Floyd, Edgar L Ready, Sarbodeep Paul, Fadeela Sheini, Rati Sharma, Robert F Rosencrans, Sergio Li Calzi, Micheli Severo Sielski, Nicholas G Medawar, Roshan Dutta, Emory Brennis Johnson, Xiaoping Qi, Mohit Bansal, Regina Lamendella, Justin R Wright, Suresh Kumar Verma, Michael E Boulton, Bruce R Stevens, Craig W Vander Kooi, Ramon C Sun, Gavin Y Oudit, Qiuhong Li, Maria B Grant

  • May 1, 2026

Related Content

Permanent J-Code for Epioxa

Glaukos secures permanent J-code from CMS ahead of July rollout

  • April 22, 2026

  • 2 min
Phacoemulsification Training in Rwanda

How an intensive phacoemulsification training program helped develop advanced ophthalmic procedures in the country

Ocular Surface Control: A Modern Approach to Peri-operative Dry Eye Management

Join us for a focused webinar exploring a modern approach to peri-operative dry eye management

  • April 22, 2026